Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share. As the first and ...

Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Mizuho analyst Uy Ear says that while Biogen’s (BIIB) offer for Sage Therapeutics (SAGE) is a 30% premium to Sage’s Friday’s closing price, ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...